Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.

Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R.

Clin Cancer Res. 2018 Nov 9. doi: 10.1158/1078-0432.CCR-18-2743. [Epub ahead of print]

PMID:
30413526
2.

Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.

Strati P, Fanale M, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2018 Sep 6. pii: haematol.2018.199844. doi: 10.3324/haematol.2018.199844. [Epub ahead of print] No abstract available.

3.

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.

Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, Shord S, Przepiorka D, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2018 Aug 16. pii: theoncologist.2018-0222. doi: 10.1634/theoncologist.2018-0222. [Epub ahead of print]

PMID:
30115735
4.

Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.

Robinson TM, Prince GT, Thoburn C, Warlick E, Ferguson A, Kasamon YL, Borrello IM, Hess A, Smith BD.

Leuk Lymphoma. 2018 Dec;59(12):2801-2811. doi: 10.1080/10428194.2018.1443449. Epub 2018 Apr 4.

PMID:
29616857
5.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

PMID:
29452245
6.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

7.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

8.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18.

PMID:
29055682
9.

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.

Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R.

Oncologist. 2017 May;22(5):585-591. doi: 10.1634/theoncologist.2017-0004. Epub 2017 Apr 24.

10.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

11.

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, Zambidis E, Llosa NJ, Huo JS, Robey N, Holuba MJ, Kasamon YL, McCurdy SR, Ambinder R, Bolaños-Meade J, Luznik L, Fuchs EJ, Jones RJ, Cooke KR, Symons HJ.

Biol Blood Marrow Transplant. 2017 Feb;23(2):325-332. doi: 10.1016/j.bbmt.2016.11.016. Epub 2016 Nov 22.

12.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

13.

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL.

Mol Imaging Biol. 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9.

PMID:
27798787
14.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Leuk Lymphoma. 2016;57(3):666-75. doi: 10.3109/10428194.2015.1071488. Epub 2015 Oct 12.

15.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

16.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Kanakry JA, Gocke CD, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Blackford AL, Fuchs EJ, Huff CA, Borrello I, Matsui WH, Brodsky RA, Rosner GL, Shanbhag S, Luznik L, Jones RJ, Ambinder RF, Kasamon YL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2115-2122. doi: 10.1016/j.bbmt.2015.07.012. Epub 2015 Jul 14.

17.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

18.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

19.

HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.

Crane GM, Ambinder RF, Shirley CM, Fishman EK, Kasamon YL, Taube JM, Borowitz MJ, Duffield AS.

Am J Surg Pathol. 2014 Mar;38(3):426-32. doi: 10.1097/PAS.0000000000000128.

20.

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE, Ambinder RF, Ghosh N.

Ann Hematol. 2014 Jul;93(7):1245-6. No abstract available.

21.

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.

Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M, Rosner GL, Levitsky HI, Hourigan CS.

Blood Cancer J. 2013 Sep 6;3:e145. doi: 10.1038/bcj.2013.44.

22.

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Kanakry JA, Kasamon YL, Bolaños-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen LJ, Symons HJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1514-7. doi: 10.1016/j.bbmt.2013.07.013. Epub 2013 Jul 18.

23.

Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.

Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6. doi: 10.1016/j.bbmt.2013.01.006. Epub 2013 Jan 29.

24.

Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies.

Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE, Brodsky RA, Jones RJ, Leffell MS.

Biol Blood Marrow Transplant. 2013 Apr;19(4):647-52. doi: 10.1016/j.bbmt.2013.01.016. Epub 2013 Jan 22.

25.

Blastic transformation of mantle cell lymphoma.

Kasamon YL, Burns KH.

Blood. 2012 Sep 20;120(12):2359. No abstract available.

26.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.

Kasamon YL, Brodsky RA, Borowitz MJ, Ambinder RF, Crilley PA, Cho SY, Tsai HL, Smith BD, Gladstone DE, Carraway HE, Huff CA, Matsui WH, Bolaños-Meade J, Jones RJ, Swinnen LJ.

Leuk Lymphoma. 2013 Mar;54(3):483-90. doi: 10.3109/10428194.2012.715346. Epub 2012 Aug 17.

27.

Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

Terezakis SA, Kasamon YL.

Crit Rev Oncol Hematol. 2012 Oct;84(1):71-84. doi: 10.1016/j.critrevonc.2012.02.006. Epub 2012 Mar 29. Review.

28.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF.

Blood. 2012 May 3;119(18):4129-32. doi: 10.1182/blood-2012-01-402792. Epub 2012 Feb 16.

29.

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.

Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ.

Pediatr Rep. 2011 Jun 22;3 Suppl 2:e15. doi: 10.4081/pr.2011.s2.e15.

30.

Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Munchel AT, Kasamon YL, Fuchs EJ.

Best Pract Res Clin Haematol. 2011 Sep;24(3):359-68. doi: 10.1016/j.beha.2011.05.001. Epub 2011 Jul 13.

31.

Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.

Kasamon YL.

Adv Hematol. 2011;2011:271595. doi: 10.1155/2011/271595. Epub 2010 Dec 22.

32.

Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.

Kasamon YL, Jones RJ, Gocke CD, Blackford AL, Seifter EJ, Davis-Sproul JM, Gore SD, Ambinder RF.

Biol Blood Marrow Transplant. 2011 Mar;17(3):365-73. doi: 10.1016/j.bbmt.2010.07.007. Epub 2010 Jul 22.

33.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

34.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N, Huff CA, Brodsky RA, Matsui WH, Swinnen LJ, Borrello I, Powell JD, Ambinder RF, Jones RJ, Fuchs EJ.

Biol Blood Marrow Transplant. 2010 Apr;16(4):482-9. doi: 10.1016/j.bbmt.2009.11.011. Epub 2010 Jan 18.

35.

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

Kasamon YL, Jones RJ, Brodsky RA, Fuchs EJ, Matsui W, Luznik L, Powell JD, Blackford AL, Goodrich A, Gocke CD, Abrams RA, Ambinder RF, Flinn IW.

Ann Oncol. 2010 Jun;21(6):1203-10. doi: 10.1093/annonc/mdp484. Epub 2009 Oct 30.

36.

Circulating clonotypic B cells in classic Hodgkin lymphoma.

Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, Lemas MV, Brennan S, Ambinder RF, Matsui W.

Blood. 2009 Jun 4;113(23):5920-6. doi: 10.1182/blood-2008-11-189688. Epub 2009 Feb 2.

37.

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, Rogers KM, Bolaños-Meade J, Borowitz MJ, Ambinder RF, Jones RJ, Swinnen LJ.

Biol Blood Marrow Transplant. 2009 Feb;15(2):242-8. doi: 10.1016/j.bbmt.2008.11.026.

38.

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.

Bolaños-Meade J, Luznik L, Muth M, Matsui WH, Huff CA, Smith BD, Levy MY, Kasamon YL, Swinnen LJ, Powell JD, Brodsky RA, Ambinder RF, Jones RJ, Fuchs EJ.

Bone Marrow Transplant. 2009 Mar;43(6):477-80. doi: 10.1038/bmt.2008.353. Epub 2008 Nov 3.

39.

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.

Kasamon YL, Wahl RL.

Curr Opin Oncol. 2008 Mar;20(2):206-19. doi: 10.1097/CCO.0b013e3282f5123d. Review.

40.

Immunotherapies for Hodgkin's lymphoma.

Kasamon YL, Ambinder RF.

Crit Rev Oncol Hematol. 2008 May;66(2):135-44. Epub 2007 Nov 19. Review.

41.

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-91. Epub 2007 Aug 3.

42.

Blood or marrow transplantation for mantle cell lymphoma.

Kasamon YL.

Curr Opin Oncol. 2007 Mar;19(2):128-35. Review.

PMID:
17272985
43.

Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.

Kasamon YL, Jones RJ, Wahl RL.

J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S. Review.

44.

Management of symptomatic, untreated chronic lymphocytic leukemia.

Kasamon YL, Flinn IW.

Blood Rev. 2007 May;21(3):143-56. Epub 2006 Nov 13. Review.

PMID:
17097783
45.

Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.

Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC.

Clin Cancer Res. 2005 Dec 1;11(23):8413-7.

46.

AIDS-related primary central nervous system lymphoma.

Kasamon YL, Ambinder RF.

Hematol Oncol Clin North Am. 2005 Aug;19(4):665-87, vi-vii. Review.

PMID:
16083829
47.

High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.

Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW.

Biol Blood Marrow Transplant. 2005 Feb;11(2):93-100.

48.

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RA, Zhang Z, Flinn IW.

Biol Blood Marrow Transplant. 2005 Jan;11(1):39-46.

49.

Treatment advances in adult Burkitt lymphoma and leukemia.

Kasamon YL, Swinnen LJ.

Curr Opin Oncol. 2004 Sep;16(5):429-35. Review.

PMID:
15314510
50.

FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy.

Kasamon YL, Wahl RL, Swinnen LJ.

Curr Opin Oncol. 2004 Mar;16(2):100-5. Review.

PMID:
15075899

Supplemental Content

Loading ...
Support Center